| |
Plasm methylome
|
Tissue qMSP
|
Plasm BSP
|
|---|
| |
HC1
|
CHB2
|
LC3
|
HCC4
|
NSCLC5
|
HC1
|
LC3
|
HCC4
|
HC1
|
CHB2
|
LC3
|
HCC4
|
|---|
|
Cases
|
31
|
30
|
27
|
29
|
26
|
10
|
29
|
33
|
37
|
36
|
40
|
47
|
|
Gender
| | | | | | | | | | | | |
|
Male
|
28 (90.3%)
|
27 (90.0%)
|
24 (88.9%)
|
26 (89.7%)
|
23 (88.5%)
|
6 (60%)
|
25 (86.2%)
|
27 (84.9%)
|
30 (81.1%)
|
28 (77.6%)
|
33 (78.8%)
|
39 (83.0%)
|
|
Female
|
3 (9.7%)
|
3 (10.0%)
|
3 (11.1%)
|
3 (10.3%)
|
3 (11.5%)
|
4 (40%)
|
4 (13.8%)
|
6 (15.1%)
|
7 (18.9%)
|
8 (22.2%)
|
7 (21.2%)
|
8 (17.0%)
|
|
Age
|
50.3 ± 8.6
|
50.7 ± 7.6
|
50.8 ± 9.6
|
55.8 ± 8.5
|
52.4 ± 9.6
|
42.2 ± 6.53
|
46.9 ± 9.2
|
50.3 ± 9.1
|
53.32 ± 5.3
|
52.53 ± 4.7
|
48.89 ± 10.7
|
54.29 ± 8.3
|
|
HBV infection
| | | | | | | | | | | | |
|
Yes
|
0 (0%)
|
30 (100%)
|
27 (100%)
|
29 (100%)
|
0 (0%)
|
0 (0%)
|
30 (100%)
|
33 (100%)
|
0 (0%)
|
36 (100%)
|
40 (100%)
|
47 (100%)
|
|
No
|
31(100%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
29 (100%)
|
10(100%)
|
0 (0%)
|
0 (0%)
|
37 (100%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
|
Differentiation
| | | | | | | | | | | | |
|
Poor
| |
/
|
/
|
11 (37.9%)
|
12 (46.2%)
|
/
|
/
|
15 (45.5%)
|
/
|
/
|
/
|
22 (46.8%)
|
|
Moderate
| |
/
|
/
|
10 (34.5%)
|
8 (30.7%)
|
/
|
/
|
13 (39.4)
|
/
|
/
|
/
|
15 (31.9%)
|
|
High
| |
/
|
/
|
8(27.6%)
|
6 (23.1%)
|
/
|
/
|
5 (15.1%)
|
/
|
/
|
/
|
10 (21.3%)
|
|
Tumor stage
| | | | | | | | | | | | |
|
I/II
| |
/
|
/
|
14 (48.3%)
|
10 (38.5%)
|
/
|
/
|
13 (39.4%)
|
/
|
/
|
/
|
12 (25.5%)
|
|
III/IV
| |
/
|
/
|
15 (51.7)
|
16 (61.5%)
|
/
|
/
|
20 (60.6%)
|
/
|
/
|
/
|
35 (74.5%)
|
|
Tumor size
| | | | | | | | | | | | |
|
≤3cm
| |
/
|
/
|
16 (55.2%)
|
/
|
/
|
/
|
11 (33.3%)
|
/
|
/
|
/
|
16 (34.1%)
|
|
>3cm
| |
/
|
/
|
13 (44.8%)
|
/
|
/
|
/
|
22 (66.7%)
|
/
|
/
|
/
|
31 (65.9%)
|
